Industry Information


  Urofollitropin is a medication used to treat infertility in women, particularly those undergoing assisted reproductive technologies such as in vitro fertilization. It is a human follicle-stimulating hormone (FSH) that is produced by recombinant DNA technology.

  This medication is similar to the FSH hormone naturally produced by the pituitary gland, which stimulates the ovaries to produce mature eggs. However, in some infertility cases, the body may not produce enough FSH, leading to irregular ovulation or the absence of ovulation altogether. Urofollitropin works by increasing the amount of FSH in the body, thus promoting the growth and maturation of ovarian follicles and increasing the chances of successful ovulation.


  Urofollitropin is administered via injection and is typically given daily for several days at the beginning of a woman's menstrual cycle. The exact dosage and duration of treatment varies depending on the individual's specific infertility issues and treatment plan.

  One potential side effect of urofollitropin is ovarian hyperstimulation syndrome (OHSS), which can occur when the ovaries are overstimulated and produce too many follicles. This can lead to symptoms such as abdominal pain, bloating, and difficulty breathing. OHSS is a serious condition that requires medical attention.

  Overall, urofollitropin is a valuable medication for women struggling with infertility. While its use may lead to some risks, the benefits of successful ovulation and potential pregnancy often outweigh these concerns. With proper medical supervision and care, urofollitropin has helped countless couples achieve their dreams of starting a family.